For non‐SQ NSCLC patients, PD‐L1 expression status was available for 40 of 76 (88.9%) patients, and the proportions of patients with PD‐L1 expression <1%, 1%–<50%, and ≥50% were 32.5%, 50.0%, and 17.5%, respectively (Table 1). Here, CD274 is linked to non-small cell lung carcinoma.